Kredex

Carvedilol, the active ingredient in Kredex, is a beta blocker (non‑selective) with alpha‑1 blocking activity presented as an oral tablet for oral use. It reduces blood pressure and improves cardiac function, and is indicated for the management of hypertension, chronic heart failure, and left ventricular dysfunction in adult patients.

GNH USA supplies Kredex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Kredex (carvedilol) is employed in cardiovascular therapy to control blood pressure and improve heart performance.

- Hypertension: lowers systolic and diastolic pressure, reducing cardiovascular risk. - Chronic heart failure: improves left ventricular ejection fraction and decreases hospitalisation rates. - Left ventricular dysfunction: enhances myocardial contractility and mitigates symptoms of reduced cardiac output.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness. - Fatigue or tiredness. - Headache. - Nausea. - Peripheral edema. - Hypotension.

Serious or Rare Side Effects: - Bronchospasm, especially in patients with asthma or COPD. - Severe bradycardia or heart block. - Worsening heart failure. - Hepatic dysfunction or jaundice. - Allergic reactions such as rash or angioedema. - Cardiogenic shock.

Before initiating therapy, clinicians should evaluate cardiovascular status and comorbid conditions.

- Monitor blood pressure: adjust dose if hypotension occurs. - Assess cardiac function: regular echocardiography for heart‑failure patients. - Use caution in asthma or COPD: β2‑blockade may precipitate bronchospasm. - Adjust dose in hepatic impairment: reduced metabolism may increase exposure. - Avoid abrupt discontinuation: taper to prevent rebound tachycardia. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Carvedilol may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Concomitant use with other β‑blockers: risk of excessive bradycardia and hypotension. - Potent CYP2D6 inhibitors (e.g., quinidine, paroxetine): may increase carvedilol plasma levels. - Strong vasodilators (e.g., nitroglycerin) combined with high doses: can cause severe hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring. - Calcium‑channel blockers (especially verapamil, diltiazem): may increase bradycardia risk. - NSAIDs: may blunt antihypertensive efficacy. - Antidiabetic agents: carvedilol can mask hypoglycaemia symptoms; monitor glucose closely.